Gate Bioscience, a biotechnology company developing a new class of small molecule medicines to eliminate disease-causing proteins at their source, today announced the appointment of Jeff Hatfield to its Board of Directors.

Can the course of fatal prion diseases be changed by removing the protein before it goes bad?

Gate Bio emerged from stealth with a $60M series A and a small molecule platform for selective gating of protein secretion

Gate Bioscience has raised $60 million to develop a new type of pill-based medicine — which it calls a molecular gate — that can go after the spectrum of malicious proteins.

The company last year raised a $60 million Series A round led by Versant Ventures and Andreessen Horowitz and including ARCH Venture Partners and GV.